This is an early development, service provider, and formulation group with the robust cutting edge technology transfer and M & A capabilities. It is a small yet very capable system of nimble technology centric system of practitioners and scientist in the area of Immune- Oncology (I- O) and Immunotherapy. It reported positive results in its Specific Conjugate Particles system with the ability to hybrid particle system of chemo. Furthermore it has provided triple negative breast cancer, non-small cell lung cancer, head and neck cancer, bladder cancer, stomach cancer, as well as cervical cancer capabilities with positive clinical trial results. SCP- Chemo area of GAP has potential ability of producing about 114 products in different therapeutic area and 11 products in I- O theater.

"We've now revealed tremendous HEOR- based efficiency against four cancers," Timothy Allen, Executive Director of Clinical Development said in an interview. "There's marvelous exhilaration in the oncology community" about SCP- Chemo and ADC.

We have reported our latest results during our launching of Nexus Alliance Biopharma.

The patients got proper predicated doses of taxanes and platinums in the proper regiments of 14- 21 days as per the standard of care (SOC). The periodic TNMs have provided the information in regards to the Progression Free Survivals as well as the Overall survivals.

Although 48 percent had some tumor shrinkage, 29 percent had tumors reduction in size and solitaires at least 56 percent. Of those, there had been may CRs, and PRs as well as a great deal of SDs. Patients are allowed to receive multiple regiments in a safer risk benefit ratio approach with a favored system of therapy vs. overall safety of the patients. Noted: The number of new patients in breast cancer alone is at about 124.6 per 100,000 women per year in the United States (US). Its mortality is about 22.2 per 100,000 women per year. The rates are age adjusted, of course. At least 12.3 percent of all women in the US will be diagnosed with breast cancer at some point of their life. There are currently 3M women living with their breast cancer in the US. Furthermore: There are approximately 21 per 100K men in new indicated bladder cancer per year in the US alone. Almost 4.5 out of 100K men and women will die of bladder cancer. The rates are age adjusted.

Approximately 2.5 percent of all men and women will be stricken by bladder cancer at some point of their lifetime. There are approximately 580K patients living with their bladder cancer in the US.

Additional information may be provided by visiting www.gapsos.com